help button home button Endocrine Society JCEM JCEM Call for Nominations for EIC
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a related Letter to the Editor
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Baker, V. L.
Right arrow Articles by Jaffe, R. B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Baker, V. L.
Right arrow Articles by Jaffe, R. B.
The Journal of Clinical Endocrinology & Metabolism Vol. 83, No. 1 6-13
Copyright © 1998 by The Endocrine Society

Original Studies

Reproductive Endocrine and Endometrial Effects of Raloxifene Hydrochloride, a Selective Estrogen Receptor Modulator, in Women with Regular Menstrual Cycles1

Valerie L. Baker, Michael Draper, Sofia Paul, Sandy Allerheiligen, Michael Glant, Jan Shifren and Robert B. Jaffe

Reproductive Endocrinology Center, Department of Obstetrics, Gynecology, and Reproductive Sciences, University of California (V.L.B., J.S., R.B.J.), San Francisco, California 94143; Eli Lilly Co. (M.D., S.P., S.A.), Indianapolis, Indiana 46285; Diagnostic Cytology Laboratories (M.G.), Indianapolis, Indiana 46268

Address all correspondence and requests for reprints to: Robert B. Jaffe, M.D., Reproductive Endocrinology Center, Department of Obstetrics, Gynecology, and Reproductive Sciences, University of California, San Francisco, California 94143-0556.

Previous studies of raloxifene conducted in animal models and postmenopausal women have demonstrated antiestrogenic action on the endometrium. The purpose of this first study of raloxifene in women with normal menstrual cycles was to determine its reproductive endocrine and endometrial effects. In part I, raloxifene (400 mg) was administered for 5 days in the follicular, periovulatory, or luteal phase of the menstrual cycle (n = 12). In part II, women were randomized to receive raloxifene (100 or 200 mg) for 28 days beginning on day 3 of the cycle (n = 19). All women ovulated in both parts of the study. Raloxifene did not alter the length of the menstrual cycle or the day of the LH surge. A 5-day course of raloxifene administered in any phase of the cycle elevated FSH area under the curve (AUC) for the entire cycle and estradiol AUC for the second half of the cycle compared with those in control cycles. In part II, raloxifene also appeared to increase the FSH AUC and estradiol AUC. Raloxifene decreased the number of gland mitoses in follicular phase endometrial biopsies. Subtle effects suggestive of gland-stromal dysynchrony were noted in a limited number of the secretory phase endometrial biopsies.

This study has demonstrated that 1) raloxifene does not prevent ovulation in women with normal menstrual cycles; 2) ovarian estrogen production will continue, and in some cases increase, in response to raloxifene; and 3) antiestrogenic effects of raloxifene on the endometrium are subtle in the endocrine milieu of normal to high circulating estradiol concentrations.




This article has been cited by other articles:


Home page
 Obstet GynecolHome page
P. Stratton, N. Sinaii, J. Segars, D. Koziol, R. Wesley, C. Zimmer, C. Winkel, and L. K. Nieman
Return of Chronic Pelvic Pain From Endometriosis After Raloxifene Treatment: A Randomized Controlled Trial
Obstet. Gynecol., January 1, 2008; 111(1): 88 - 96.
[Abstract] [Full Text] [PDF]

Home page
 Protein Sci.Home page
F. F. Vajdos, L. R. Hoth, K. F. Geoghegan, S. P. Simons, P. K. LeMotte, D. E. Danley, M. J. Ammirati, and J. Pandit
The 2.0 A crystal structure of the ER{alpha} ligand-binding domain complexed with lasofoxifene
Protein Sci., May 1, 2007; 16(5): 897 - 905.
[Abstract] [Full Text] [PDF]

Home page
 J EndocrinolHome page
R. T Chatterton Jr, J. Zujewski, E. T Mateo, J. Eng-Wong, and V C. Jordan
Effect of raloxifene on salivary sex steroid concentrations in premenopausal women
J. Endocrinol., December 1, 2006; 191(3): 599 - 604.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
K. A. Johnson
The SERM of My Dreams.
J. Clin. Endocrinol. Metab., October 1, 2006; 91(10): 3754 - 3756.
[Full Text] [PDF]

Home page
 Cancer Epidemiol. Biomarkers Prev.Home page
J. M. Faupel-Badger, S. A. Prindiville, D. Venzon, B. K. Vonderhaar, J. A. Zujewski, and J. Eng-Wong
Effects of raloxifene on circulating prolactin and estradiol levels in premenopausal women at high risk for developing breast cancer.
Cancer Epidemiol. Biomarkers Prev., June 1, 2006; 15(6): 1153 - 1158.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
C. J. Fabian and B. F. Kimler
Selective Estrogen-Receptor Modulators for Primary Prevention of Breast Cancer
J. Clin. Oncol., March 10, 2005; 23(8): 1644 - 1655.
[Full Text] [PDF]

Home page
 Mol. Biol. CellHome page
M. Kian Tee, I. Rogatsky, C. Tzagarakis-Foster, A. Cvoro, J. An, R. J. Christy, K. R. Yamamoto, and D. C. Leitman
Estradiol and Selective Estrogen Receptor Modulators Differentially Regulate Target Genes with Estrogen Receptors {alpha} and {beta}
Mol. Biol. Cell, March 1, 2004; 15(3): 1262 - 1272.
[Abstract] [Full Text] [PDF]

Home page
 Mol Cancer ResHome page
L. C. Hodges, J. D. Cook, E. K. Lobenhofer, L. Li, L. Bennett, P. R. Bushel, C. M. Aldaz, C. A. Afshari, and C. L. Walker
Tamoxifen Functions As a Molecular Agonist Inducing Cell Cycle-Associated Genes in Breast Cancer Cells
Mol. Cancer Res., February 1, 2003; 1(4): 300 - 311.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
S. Palomba, F. Orio Jr., M. Morelli, T. Russo, M. Pellicano, E. Zupi, G. Lombardi, C. Nappi, P. L. B. Panici, and F. Zullo
Raloxifene Administration in Premenopausal Women with Uterine Leiomyomas: A Pilot Study
J. Clin. Endocrinol. Metab., August 1, 2002; 87(8): 3603 - 3608.
[Abstract] [Full Text] [PDF]

Home page
 Ann. N. Y. Acad. Sci.Home page
D. P. McDONNELL, C.-Y. CHANG, and J. D. NORRIS
Capitalizing on the Complexities of Estrogen Receptor Pharmacology in the Quest for the Perfect SERM
Ann. N.Y. Acad. Sci., December 1, 2001; 949(1): 16 - 35.
[Abstract] [Full Text] [PDF]

Home page
 Ann. N. Y. Acad. Sci.Home page
L. PLOUFFE JR. and S. SIDDHANTI
The Effect of Selective Estrogen Receptor Modulators on Parameters of the Hypothalamic-Pituitary-Gonadal Axis
Ann. N.Y. Acad. Sci., December 1, 2001; 949(1): 251 - 258.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
C. E. Connor, J. D. Norris, G. Broadwater, T. M. Willson, M. M. Gottardis, M. W. Dewhirst, and D. P. McDonnell
Circumventing Tamoxifen Resistance in Breast Cancers Using Antiestrogens That Induce Unique Conformational Changes in the Estrogen Receptor
Cancer Res., April 1, 2001; 61(7): 2917 - 2922.
[Abstract] [Full Text]

Home page
 Proc. Natl. Acad. Sci. USAHome page
J. An, R. C. J. Ribeiro, P. Webb, J.-A. Gustafsson, P. J. Kushner, J. D. Baxter, and D. C. Leitman
Estradiol repression of tumor necrosis factor-alpha transcription requires estrogen receptor activation function-2 and is enhanced by coactivators
PNAS, December 21, 1999; 96(26): 15161 - 15166.
[Abstract] [Full Text] [PDF]

Home page
 Endocr. Rev.Home page
V. C. Jordan and M. Morrow
Tamoxifen, Raloxifene, and the Prevention of Breast Cancer
Endocr. Rev., June 1, 1999; 20(3): 253 - 278.
[Abstract] [Full Text]

Home page
 Endocr. Rev.Home page
F. Cosman and R. Lindsay
Selective Estrogen Receptor Modulators: Clinical Spectrum
Endocr. Rev., June 1, 1999; 20(3): 418 - 434.
[Abstract] [Full Text]

Home page
 JCOHome page
R. T. Chlebowski, D. E. Collyar, M. R. Somerfield, and D. G. Pfister
American Society of Clinical Oncology Technology Assessment on Breast Cancer Risk Reduction Strategies: Tamoxifen and Raloxifene
J. Clin. Oncol., June 1, 1999; 17(6): 1939 - 1939.
[Abstract] [Full Text] [PDF]

Home page
 ANN INTERN MEDHome page
W. Khovidhunkit and D. M. Shoback
Clinical Effects of Raloxifene Hydrochloride in Women
Ann Intern Med, March 2, 1999; 130(5): 431 - 439.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
Y. Sadovsky and S. Adler
Editorial: Selective Modulation of Estrogen Receptor Action
J. Clin. Endocrinol. Metab., January 1, 1998; 83(1): 3 - 5.
[Full Text]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 1998 by The Endocrine Society